As drugmakers strive to fine tune the delivery of their medications for better convenience and patient adherence, Halozyme is putting a recent acquisition in the space to work, thanks to a new tie- | ...

Vertex Pharmaceuticals (VRTX) is back in focus after the U.S. Food and Drug Administration expanded use of its cystic ...

Under the agreement, Vertex will make a $15m upfront payment to Halozyme and potential future milestone payments.

The biotech's recent dip might be a buying opportunity.

Halozyme Therapeutics (NASDAQ:HALO) said its subsidiary has entered into an exclusive collaboration and licensing agreement with Vertex Pharmaceuticals (NASDAQ:VRTX) covering the use of Halozyme’s ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2026 financial results on Monday, May 4, ...

Novo escalated a GLP-1 pricing war with the launch of its newest obesity medicine. Elsewhere, analysts came to Insmed’s defense and HHS changed the way panelists for a key vaccine committee are ...

Vertex Pharmaceuticals is acquiring immune therapies developer Alpine Immune Sciences in a $4.9 billion deal whose centerpiece is a Phase 3-ready drug for a chronic kidney disorder with few treatment ...

Vertex Pharmaceuticals stock is a "Strong Buy", driven by robust CF franchise growth and successful label expansions for ...

Security researchers have identified a vulnerability in Google’s Vertex AI agent framework that could allow attackers to ...

Unit 42 found excessive P4SA permissions in Vertex AI, enabling credential theft and cloud data exposure, increasing breach ...